Compare Northrop Grumman Corporation (NOC) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs Novartis AG — how do they compare? Northrop Grumman Corporation trades at $480.72 (market cap $68.83B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 3.9× Northrop Grumman Corporation's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Northrop Grumman Corporation for 81 Days and Novartis AG for 82 Days on average.
| NOC | NVS | |
|---|---|---|
Market Cap | $68.83B | $268.57B |
Volume | 1,081,989 | 1,532,573 |
Sector | Industrials | Health |
52-Week High | $768.02 | $168.62 |
52-Week Low | $473.46 | $121.80 |
Typical Hold Time | 81 Days | 82 Days |
Enterprise Value | $82.81B | $309.89B |
Dividend Yield | 2.04% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $484.48, up 2.33% today, but technical indicators signal a bearish trend with the stock below key moving averages. Fundamentally, the company shows strength with a P/E of 15.4, robust profitability margins, and consistent earnings beats in recent quarters. Recent news highlights a mixed environment, including a significant contract loss to Boeing but sustained demand from defense budgets and a record backlog supporting future revenue.
The outlook remains positive due to strong fundamentals and analyst consensus, with a price target of $600.62 implying substantial upside. Key risks include competitive pressures from recent contract losses and dependence on government spending, but the company's financial health and dividend payments provide stability for investors.
NVS trades at $143.11, down 0.12% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company maintains strong profitability with a 22.5% net income margin and 30.55% ROE, while recent news highlights a major $7.8B licensing deal with China's Abogen and ongoing investor scrutiny following clinical trial setbacks.
The outlook is cautious; analyst consensus is a Hold with a $146 price target, but risks include pipeline disappointments and M&A execution. Upside hinges on successful drug launches and deal integration, while downside stems from competitive pressures and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
